Cargando…
Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination
The global COVID-19 vaccination had an undeniable influence on the pandemic management, despite of having reported rare but life-threatening side-effects of vaccines. Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare autoimmune complication determined by thrombocytopenia and thromb...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
UMF “Gr. T. Popa” Iasi Publishing House
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769072/ https://www.ncbi.nlm.nih.gov/pubmed/36628165 http://dx.doi.org/10.22551/2022.37.0904.10222 |
_version_ | 1784854308256219136 |
---|---|
author | Zaheri, Hamidreza Kiani, Arda Afaghi, Siamak Rahimi, Fatemehsadat Banitorfi, Mohammadhossein Norozi, Amirmohammad Kazemzadeh Hashemi, Samaneh Abedini, Atefeh |
author_facet | Zaheri, Hamidreza Kiani, Arda Afaghi, Siamak Rahimi, Fatemehsadat Banitorfi, Mohammadhossein Norozi, Amirmohammad Kazemzadeh Hashemi, Samaneh Abedini, Atefeh |
author_sort | Zaheri, Hamidreza |
collection | PubMed |
description | The global COVID-19 vaccination had an undeniable influence on the pandemic management, despite of having reported rare but life-threatening side-effects of vaccines. Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare autoimmune complication determined by thrombocytopenia and thrombosis propensity in the circulatory system. The activation of antibodies against platelet factor-4 (PF-4) which mimics the heparin-induced thrombocytopenia (HIT) characteristic is the main known pathogenicity of the disease. Herein, we reported a case of VITT in a middle-aged woman with no previous history of thrombophilia or other medical conditions who presented with thrombosis of the left superficial femoral artery 3-days after receiving the second dose of inactivated BBIBP-CorV (Sinopharm) vaccine. The patient underwent bypass vascular surgery and received none-heparin anticoagulation consistent with high-dose intravenous immunoglobin. Eight days after the discharge, she was subsequently referred to our center with the presentation of sub-massive pulmonary thromboembolism in spite of receiving the prophylactic anticoagulants during follow-up period. Details on side-effects of COVID-19 vaccines, specifically the inactivated ones are yet to be fully ascertained. Clinicians should consider the history of COVID-19 vaccines in thromboembolism patients who do not have well-acknowledged risk factors. Further studies about the necessity of prophylactic anticoagulants and clinical judgment for receiving other vaccines in such patients are required. |
format | Online Article Text |
id | pubmed-9769072 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | UMF “Gr. T. Popa” Iasi Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-97690722023-01-09 Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination Zaheri, Hamidreza Kiani, Arda Afaghi, Siamak Rahimi, Fatemehsadat Banitorfi, Mohammadhossein Norozi, Amirmohammad Kazemzadeh Hashemi, Samaneh Abedini, Atefeh Arch Clin Cases Case Report The global COVID-19 vaccination had an undeniable influence on the pandemic management, despite of having reported rare but life-threatening side-effects of vaccines. Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare autoimmune complication determined by thrombocytopenia and thrombosis propensity in the circulatory system. The activation of antibodies against platelet factor-4 (PF-4) which mimics the heparin-induced thrombocytopenia (HIT) characteristic is the main known pathogenicity of the disease. Herein, we reported a case of VITT in a middle-aged woman with no previous history of thrombophilia or other medical conditions who presented with thrombosis of the left superficial femoral artery 3-days after receiving the second dose of inactivated BBIBP-CorV (Sinopharm) vaccine. The patient underwent bypass vascular surgery and received none-heparin anticoagulation consistent with high-dose intravenous immunoglobin. Eight days after the discharge, she was subsequently referred to our center with the presentation of sub-massive pulmonary thromboembolism in spite of receiving the prophylactic anticoagulants during follow-up period. Details on side-effects of COVID-19 vaccines, specifically the inactivated ones are yet to be fully ascertained. Clinicians should consider the history of COVID-19 vaccines in thromboembolism patients who do not have well-acknowledged risk factors. Further studies about the necessity of prophylactic anticoagulants and clinical judgment for receiving other vaccines in such patients are required. UMF “Gr. T. Popa” Iasi Publishing House 2022-12-19 /pmc/articles/PMC9769072/ /pubmed/36628165 http://dx.doi.org/10.22551/2022.37.0904.10222 Text en https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Zaheri, Hamidreza Kiani, Arda Afaghi, Siamak Rahimi, Fatemehsadat Banitorfi, Mohammadhossein Norozi, Amirmohammad Kazemzadeh Hashemi, Samaneh Abedini, Atefeh Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination |
title | Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination |
title_full | Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination |
title_fullStr | Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination |
title_full_unstemmed | Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination |
title_short | Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination |
title_sort | lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after sinopharm bbibp-corv covid-19 vaccination |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769072/ https://www.ncbi.nlm.nih.gov/pubmed/36628165 http://dx.doi.org/10.22551/2022.37.0904.10222 |
work_keys_str_mv | AT zaherihamidreza lowerlimbarterialthrombosisfollowedbysubmassivepulmonarythromboembolismaftersinopharmbbibpcorvcovid19vaccination AT kianiarda lowerlimbarterialthrombosisfollowedbysubmassivepulmonarythromboembolismaftersinopharmbbibpcorvcovid19vaccination AT afaghisiamak lowerlimbarterialthrombosisfollowedbysubmassivepulmonarythromboembolismaftersinopharmbbibpcorvcovid19vaccination AT rahimifatemehsadat lowerlimbarterialthrombosisfollowedbysubmassivepulmonarythromboembolismaftersinopharmbbibpcorvcovid19vaccination AT banitorfimohammadhossein lowerlimbarterialthrombosisfollowedbysubmassivepulmonarythromboembolismaftersinopharmbbibpcorvcovid19vaccination AT noroziamirmohammadkazemzadeh lowerlimbarterialthrombosisfollowedbysubmassivepulmonarythromboembolismaftersinopharmbbibpcorvcovid19vaccination AT hashemisamaneh lowerlimbarterialthrombosisfollowedbysubmassivepulmonarythromboembolismaftersinopharmbbibpcorvcovid19vaccination AT abediniatefeh lowerlimbarterialthrombosisfollowedbysubmassivepulmonarythromboembolismaftersinopharmbbibpcorvcovid19vaccination |